Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.05B |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.61B |
| 3 |
Tesla
TSLA
|
+$636M |
| 4 |
TSMC
TSM
|
+$604M |
| 5 |
iShares Bitcoin Trust
IBIT
|
+$330M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.25B |
| 2 |
Apple
AAPL
|
+$1.13B |
| 3 |
Microsoft
MSFT
|
+$988M |
| 4 |
Meta Platforms (Facebook)
META
|
+$572M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$570M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 1.55% |
| 2 | Consumer Discretionary | 0.95% |
| 3 | Financials | 0.77% |
| 4 | Healthcare | 0.67% |
| 5 | Industrials | 0.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGIG
12026
CALL
Abundia Global Impact Group
AGIG
$41.1M
| $28.6K | ﹤0.01% |
3,720
+1,410
| +61% | +$18.5K |
|
12027
CALL
DocGo
DCGO
$37.8M
| $28.5K | ﹤0.01% |
+10,800
| New | +$43.3K |
|
12028
Fathom Holdings
FTHM
$23.7M
| $28.5K | ﹤0.01% |
32,319
-10,202
| -24% | -$11.7K |
|
12029
PUT
Acumen Pharmaceuticals
ABOS
$224M
| $28.5K | ﹤0.01% |
25,900
-7,200
| -22% | -$10.3K |
|
|
XIN
12030
DELISTED
Xinyuan Real Estate
XIN
| $27.9K | ﹤0.01% |
+10,865
| New | +$30.2K |
|
|
BZAI
12031
PUT
Blaize Holdings
BZAI
$68.4M
| $27.9K | ﹤0.01% |
+13,800
| New | +$62.4K |
|
12032
CALL
Neumora Therapeutics
NMRA
$282M
| $27.8K | ﹤0.01% |
27,800
-410,000
| -94% | -$702K |
|
|
XHLD
12033
TEN Holdings
XHLD
$102M
| $27.6K | ﹤0.01% |
+1,842
| New | +$37.6K |
|
12034
CALL
Blink Charging
BLNK
$85.9M
| $27.5K | ﹤0.01% |
29,900
-172,600
| -85% | -$200K |
|
|
LYRA
12035
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $27.5K | ﹤0.01% |
4,351
+2,282
| +110% | +$21.3K |
|
|
FOCL
12036
PUT
EDAP TMS S.A.
FOCL
$202M
| $27.4K | ﹤0.01% |
+14,000
| New | +$33.3K |
|
12037
PUT
Protalix BioTherapeutics
PLX
$193M
| $27.4K | ﹤0.01% |
+10,700
| New | +$25.6K |
|
12038
Century Therapeutics
IPSC
$393M
| $27.3K | ﹤0.01% |
57,435
+24,040
| +72% | +$18.1K |
|
12039
374Water
SCWO
$42M
| $27.2K | ﹤0.01% |
8,005
+5,217
| +187% | +$23.1K |
|
12040
CALL
Codexis
CDXS
$184M
| $27.2K | ﹤0.01% |
10,100
-31,900
| -76% | -$124K |
|
12041
Aqua Metals
AQMS
$10.1M
| $26.8K | ﹤0.01% |
1,433
-942
| -40% | -$19.4K |
|
|
ONL
12042
CALL
Orion Office REIT
ONL
$168M
| $26.8K | ﹤0.01% |
+12,500
| New | +$43.6K |
|
|
ORIO
12043
CALL
Orion Digital Corp
ORIO
$19.8M
| $26.7K | ﹤0.01% |
31,100
-161,700
| -84% | -$184K |
|
12044
CALL
Globus Maritime Ltd
GLBS
$82.6M
| $26.7K | ﹤0.01% |
22,100
-21,400
| -49% | -$27.8K |
|
12045
PUT
Caribou Biosciences
CRBU
$189M
| $26.7K | ﹤0.01% |
29,300
+300
| +1% | +$390 |
|
|
SLRN
12046
PUT
DELISTED
ACELYRIN
SLRN
| $26.4K | ﹤0.01% |
+10,700
| New | +$25.4K |
|
12047
Bridgeline Digital
BLIN
$12.3M
| $26.3K | ﹤0.01% |
+17,798
| New | +$29.5K |
|
12048
CALL
Castor Maritime
CTRM
$24.2M
| $26.2K | ﹤0.01% |
+11,500
| New | +$30.1K |
|
12049
PUT
Atossa Therapeutics
ATOS
$26.7M
| $26.2K | ﹤0.01% |
2,607
-2,240
| -46% | -$27.2K |
|
12050
CALL
LanzaTech
LNZA
$87.2M
| $25.9K | ﹤0.01% |
+1,081
| New | +$97.3K |
|
Similar funds
Jeff Yass's Q1 2025 Portfolio in Review
As of Q1 2025, Jeff Yass held 13,842 positions worth $586B, down 12% from $663B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Jeff Yass withdrew a net $24.4B in Q1 2025, closing 1,482 positions and reducing 4,842 holdings. Its most notable exit was Inari Medical, Inc. Common Stock, an estimated $24M position sold in full.
By sector, the portfolio is most concentrated in Technology at 1.6% of assets, down from 2% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, Jeff Yass opened a new position in Brookfield Asset Management worth $86M.
- Jeff Yass's largest Q1 2025 buy was Brookfield Asset Management: 1,775,684 shares worth $86M.
- Jeff Yass added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $4.05B increase.
- Jeff Yass's biggest Q1 2025 reduction was Invesco QQQ Trust, cutting an estimated $1.25B.
- Jeff Yass fully exited Inari Medical, Inc. Common Stock in Q1 2025, selling an estimated $24M.
- Jeff Yass's ten largest holdings make up 28% of its $586B portfolio in Q1 2025.
- Jeff Yass opened 1,775 new positions and closed 1,482 in Q1 2025.
- Jeff Yass's portfolio value fell 12% quarter-over-quarter to $586B.
Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.